Assessment of joint space narrowing with conventional standing antero-posterior radiographs: relief in mild-to-moderate pain is not a confounder in recent osteoarthritis structure-modifying drug trials; ; et al in Osteoarthritis and Cartilage (2006), 14(Suppl. A), 14-18 Objective: Knee pain relief has been suggested to potentially alter radioanatomic positioning in conventional standing antero-posterior knee radiographs. This study was performed to determine whether this ... [more ▼] Objective: Knee pain relief has been suggested to potentially alter radioanatomic positioning in conventional standing antero-posterior knee radiographs. This study was performed to determine whether this is always the case and in particular if it applied to two recent randomised, placebo-controlled trials showing both symptom- and structure-modification with glucosamine sulfate in knee osteoarthritis. Design: Patients in the two studies were selected if they completed the 3-year evaluations and, irrespectively of treatment, (1) were pain-improvers in that they underwent Western Ontario and McMaster Universities (WOMAC) osteoarthritis index (WOMAC) pain decrease at least equal to the mean improvement observed with glucosamine sulfate, or (2) if their baseline standing knee pain (item #5 of the WOMAC pain scale) was "severe" or "extreme" and improved by any degree at the end of the trials. Changes in minimum joint space width were then compared between treatments. Results: Knee pain was of mild-to-moderate severity in the two original studies and in all patient subsets identified here. Obviously, there were more pain-improvers in the glucosamine sulfate than in the placebo subsets (N 76 vs 57 in pooling the two studies), but WOMAC pain scores improved to the same extent (over 50% relative to baseline). Notwithstanding such a major pain relief, patients in the placebo subsets of both studies suffered a definite mean (SE) joint space narrowing, that was of -0.22 (0.15) mm in the pooled analysis, and that was not observed with glucosamine sulfate: +0.15 (0.07) mm; P= 0.003. Similar evidence was found in the smaller subsets with at least severe baseline standing knee pain improving after 3 years. Conclusions: Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials, possibly due to the mild-to-moderate patient characteristics. Consensus deliverables should acknowledge that the potential limitations of conventional standing antero-posterior radiographs should not be overestimated since they may not apply to all patient populations and to all studies using this gold standard technique. (C) 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. [less ▲] Detailed reference viewed: 8 (3 ULg) Clinical relevance of pain and function outcomes in glucosamine sulfate long-term trials; Bruyère, Olivier ; et alin Osteoarthritis and Cartilage (2005), 13(A), 69 Detailed reference viewed: 8 (4 ULg) Responders to glucosamine sulfate in knee osteoarthritisBruyère, Olivier ; ; et alin Osteoporosis International (2004), 12(SB), 76 Detailed reference viewed: 7 (2 ULg) Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs; ; et al in Osteoarthritis and Cartilage (2002), 10(SA), 16-17 Detailed reference viewed: 11 (5 ULg) Long-term disease modifying effect by glucosamine sulfate in knee osteoarthritis : relationship between structure and symptom changesReginster, Jean-Yves ; DEROISY, Rita ; et alin Annals of the Rheumatic Diseases (2000), 59(S1), 55 Detailed reference viewed: 16 (2 ULg) Glucosamine sulfate significantly reduces progression of knee osteoarthritis over 3 years : a large randomized, placebo-controlled, double-blind, prospective trialReginster, Jean-Yves ; DEROISY, Rita ; et alin Osteoarthritis and Cartilage (2000), 8 Detailed reference viewed: 10 (2 ULg) Glucosamine sulfate significantly reduces progression of the knee osteoarthritis over 3 years : a large randomised, placebo-controlled, double-blind, prospective trialReginster, Jean-Yves ; DEROISY, Rita ; et alin Arthritis and Rheumatism (1999), 42(S1), 400 Detailed reference viewed: 8 (2 ULg) Sodium monofluorophosphate reduces vertebral fractures in moderate postmenopausal osteoporosisReginster, Jean-Yves ; ; Zegels, Brigitte et alin Journal of Bone and Mineral Research (1997), 12(S1), 104 Detailed reference viewed: 14 (2 ULg) Sodium monofluorophosphate reduces fracture incidence in women with postmenopausal osteoporosis : a randomized, placebo-controlled, double-blind study; Zegels, Brigitte ; et alin Revue du Rhumatisme (English ed.) (1996), 63 Detailed reference viewed: 2 (1 ULg) Réduction de l’incidence fracturaire vertébrale chez des femmes ostéoporotiques traitées par monofluorophosphate de sodium : une étude randomisée, placebo-controllée et double aveugle; Zegels, Brigitte ; et alin Revue du Rhumatisme (1996), 63 Detailed reference viewed: 9 (1 ULg) Monofluorophosphate decreases vertebral fracture rate in postmenopausal osteoporosis: a randomised, placebo-controlled, double blind studyReginster, Jean-Yves ; Zegels, Brigitte ; et alin Osteoporosis International (1996), 6(S1), 239 Detailed reference viewed: 3 (1 ULg) |
||